Chemed Corporation

NYSE:CHE Stok Raporu

Piyasa değeri: US$5.8b

Chemed Gelecekteki Büyüme

Future kriter kontrolleri 1/6

Chemed kazanç ve gelirinin sırasıyla yıllık 12.9% ve 6.3% oranında artması tahmin edilirken, EPS'nin yıllık 15.5% oranında büyümesi bekleniyor.

Anahtar bilgiler

12.9%

Kazanç büyüme oranı

15.53%

EPS büyüme oranı

Healthcare kazanç büyümesi18.3%
Gelir büyüme oranı6.3%
Gelecekteki özkaynak getirisin/a
Analist kapsamı

Low

Son güncelleme27 Apr 2026

Gelecekteki son büyüme güncellemeleri

Analiz Makalesi • Oct 31

Analysts Are Updating Their Chemed Corporation (NYSE:CHE) Estimates After Its Third-Quarter Results

It's been a good week for Chemed Corporation ( NYSE:CHE ) shareholders, because the company has just released its...

Recent updates

Anlatı Güncellemesi • Apr 27

CHE: Ongoing Buybacks And Earnings Guidance Will Support Balanced Future Returns

Analysts now see Chemed’s fair value holding at $443, with updated assumptions for revenue growth of 6.52%, a profit margin of 12.54%, and a future P/E of 15.49x shaping their refreshed price target rationale. What's in the News From January 1, 2026 to March 31, 2026, Chemed repurchased 500,000 shares for $197.7 million, representing 3.65% of its shares under the long running buyback program announced in February 2011 (Key Developments).
Anlatı Güncellemesi • Apr 10

CHE: Expanded Buybacks And Earnings Guidance Will Support Stronger Future Returns

Analysts have kept their price target for Chemed steady at $443. This reflects updated assumptions around slightly different revenue growth, profit margin and future P/E inputs that do not materially change their overall valuation view.
Anlatı Güncellemesi • Mar 27

CHE: Expanded Buybacks And Higher Margins Will Support Stronger Future Returns

Analysts have maintained Chemed's price target at $443, citing updated assumptions for profit margin and forward P/E as key factors behind the reaffirmed view. What's in the News Chemed issued consolidated earnings guidance for full-year 2026, with projected earnings per diluted share in a range of $23.25 to $24.25, excluding certain non cash items such as stock option expenses, tax benefits from stock option exercises, litigation costs and other discrete items (corporate guidance).
Anlatı Güncellemesi • Mar 10

CHE: Revised Outlook And Ongoing Buybacks Will Shape Balanced Future Returns

Analysts have revised their price target on Chemed to $443.00 from $555.50, reflecting updated views on revenue growth, profit margins, and the P/E multiple they consider appropriate for the stock. What's in the News Chemed issued consolidated earnings guidance for full-year 2026, projecting earnings per diluted share, excluding specified non cash and discrete items, in a range of $23.25 to $24.25 (company guidance).
Yeni Anlatı • Feb 27

Repositioned Hospice Mix And Aging Demographics Will Support Stronger Long Term Performance

Catalysts About Chemed Chemed operates VITAS Healthcare, a large hospice provider, and Roto-Rooter, a national plumbing and water restoration service business. What are the underlying business or industry changes driving this perspective?
Anlatı Güncellemesi • Feb 24

CHE: Stable Margins And Expanded Buybacks Will Support Future Upside

Analysts maintained Chemed's price target at $555.50, citing unchanged views on fair value, discount rate, revenue growth, profit margin, and future P/E assumptions. What's in the News On February 13, 2026, Chemed increased its equity buyback authorization by US$300 million to a total of US$3.05 billion under its existing repurchase program (Key Developments).
Anlatı Güncellemesi • Feb 10

CHE: Stable Margins And Consistent Assumptions Will Support Future Upside

Analysts have maintained their fair value estimate for Chemed at US$555.50 per share, with only small adjustments to inputs such as the discount rate, revenue growth, profit margin and future P/E assumptions, resulting in a marginally updated price target narrative. Valuation Changes Fair Value: Kept unchanged at US$555.50 per share, indicating no revision to the central valuation output.
Anlatı Güncellemesi • Jan 23

CHE: Share Buybacks And Margin Outlook Will Support Future Upside

Analysts now see Chemed's fair value at US$555.50, down from US$582.25. This reflects updated views on the discount rate, revenue growth, profit margin and future P/E assumptions.
Analiz Makalesi • Jan 16

Here's What Chemed's (NYSE:CHE) Strong Returns On Capital Mean

What trends should we look for it we want to identify stocks that can multiply in value over the long term? Ideally, a...
Analiz Makalesi • Oct 31

Analysts Are Updating Their Chemed Corporation (NYSE:CHE) Estimates After Its Third-Quarter Results

It's been a good week for Chemed Corporation ( NYSE:CHE ) shareholders, because the company has just released its...
Analiz Makalesi • Oct 24

Chemed Corporation (NYSE:CHE) Shares Could Be 38% Below Their Intrinsic Value Estimate

Key Insights Using the 2 Stage Free Cash Flow to Equity, Chemed fair value estimate is US$707 Chemed is estimated to be...
Seeking Alpha • Oct 06

Chemed Corp: Genius Of The Model Lies In Its Corporate Strategy

Summary Chemed Corp's unconventional structure is masterfully managed with a disciplined focus on operational excellence and shareholder-friendly capital allocation. The company's primary competitive advantage is its brand, a powerful intangible asset cultivated over nearly a century of reliable service and effective marketing. Chemed has constructed a uniquely durable enterprise built to create shareholder value for the long term. Read the full article on Seeking Alpha
Anlatı Güncellemesi • Sep 03

New Florida CON Sites Will Advance Home-Based And Hospice Care

Chemed’s modest price target increase to $582.25 reflects stable sentiment, as core metrics like future P/E and revenue growth remain virtually unchanged. What's in the News Increased equity buyback authorization by $300 million, bringing total to $2.75 billion.
Analiz Makalesi • Jul 07

Chemed Corporation (NYSE:CHE) Shares Could Be 23% Below Their Intrinsic Value Estimate

Key Insights Using the 2 Stage Free Cash Flow to Equity, Chemed fair value estimate is US$614 Chemed's US$473 share...
Analiz Makalesi • Jun 18

Chemed Corporation's (NYSE:CHE) Business Is Yet to Catch Up With Its Share Price

With a price-to-earnings (or "P/E") ratio of 25.9x Chemed Corporation ( NYSE:CHE ) may be sending bearish signals at...
User avatar
Yeni Anlatı • Aug 25

Strategic Acquisitions And Operational Efficiencies Set To Propel VITAS And Roto-Rooter Forward

Strategic acquisitions, such as Covenant Health, and aggressive hiring in VITAS are poised to enhance Chemed's revenue and net margins through improved operational efficiency.
Seeking Alpha • Aug 16

Chemed Remains A Buy On Long-Term Economics

Summary Chemed continues to present with exceptional economic characteristics now at depressed valuations vs. history. The business is highly profitable and earns high rates of return on all the capital that's been employed into its operations. Management has an extensive reinvestment runway to redeploy surplus funds and grow the intrinsic worth of the business. Read the full article on Seeking Alpha

Kazanç ve Gelir Büyüme Tahminleri

NYSE:CHE - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
TarihGelirKazançlarSerbest Nakit AkışıFaaliyetlerden NakitAvg. Analist Sayısı
12/31/20283,015N/AN/AN/A1
12/31/20272,8593273464224
12/31/20262,6922953213914
3/31/20262,541260377444N/A
12/31/20252,530265325388N/A
9/30/20252,531279360420N/A
6/30/20252,512290371427N/A
3/31/20252,489309315366N/A
12/31/20242,431302368417N/A
9/30/20242,377302313361N/A
6/30/20242,336301253300N/A
3/31/20242,293283302354N/A
12/31/20232,264273273330N/A
9/30/20232,225245259322N/A
6/30/20232,187226280345N/A
3/31/20232,165240208269N/A
12/31/20222,135250253310N/A
9/30/20222,129262220273N/A
6/30/20222,141277284334N/A
3/31/20222,142267249303N/A
12/31/20212,139269250309N/A
9/30/20212,132308271332N/A
6/30/20212,121303283344N/A
3/31/20212,091329450507N/A
12/31/20202,080319430489N/A
9/30/20202,069271410466N/A
6/30/20202,021263413470N/A
3/31/20201,992231258317N/A
12/31/20191,939220N/A301N/A
9/30/20191,874209N/A294N/A
6/30/20191,837201N/A275N/A
3/31/20191,806205N/A296N/A
12/31/20181,783206N/A287N/A
9/30/20181,753206N/A202N/A
6/30/20181,727190N/A183N/A
3/31/20181,700113N/A159N/A
12/31/20171,66798N/A162N/A
9/30/20171,64276N/A198N/A
6/30/20171,61767N/A162N/A
3/31/20171,592114N/A197N/A
12/31/20161,577109N/A135N/A
9/30/20161,572106N/A187N/A
6/30/20161,566108N/A175N/A
3/31/20161,557111N/A166N/A
12/31/20151,543110N/A172N/A
9/30/20151,524110N/A172N/A
6/30/20151,496106N/A135N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: CHE 'nin tahmini kazanç büyümesi (yıllık 12.9% ) tasarruf oranının ( 3.5% ) üzerindedir.

Kazançlar ve Piyasa: CHE şirketinin kazançlarının (yıllık 12.9% ) US pazarından (yıllık 16.7% ) daha yavaş büyümesi öngörülüyor.

Yüksek Büyüme Kazançları: CHE şirketinin kazançlarının artması bekleniyor, ancak önemli ölçüde.

Gelir ve Pazar: CHE şirketinin gelirinin (yıllık 6.3% ) US pazarından (yıllık 11.7% ) daha yavaş büyümesi öngörülüyor.

Yüksek Büyüme Geliri: CHE şirketinin gelirinin (yıllık 6.3% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: CHE 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Büyüyen şirketleri keşfedin

7D

1Y

7D

1Y

7D

1Y

Şirket Analizi ve Finansal Veri Durumu

VeriSon Güncelleme (UTC saati)
Şirket Analizi2026/05/21 13:43
Gün Sonu Hisse Fiyatı2026/05/21 00:00
Kazançlar2026/03/31
Yıllık Kazançlar2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

PaketVeriZaman ÇerçevesiÖrnek ABD Kaynağı *
Şirket Finansalları10 yıl
  • Gelir tablosu
  • Nakit akış tablosu
  • Bilanço
Analist Konsensüs Tahminleri+3 yıl
  • Finansal tahminler
  • Analist fiyat hedefleri
Piyasa Fiyatları30 yıl
  • Hisse senedi fiyatları
  • Temettüler, Bölünmeler ve Eylemler
Sahiplik10 yıl
  • En büyük hissedarlar
  • İçeriden öğrenenlerin ticareti
Yönetim10 yıl
  • Liderlik ekibi
  • Yönetim Kurulu
Önemli Gelişmeler10 yıl
  • Şirket duyuruları

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Chemed Corporation 10 Bu analistlerden 4, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

AnalistKurum
Adam FeinsteinBarclays
Joanna Sylvia GajukBofA Global Research
Peter MartinCitizens JMP Securities, LLC